Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients.
Han G, Stern A, Lee YJ, Li Y, Dahi PB, Tamari R, Gyurkocza B, Jakubowski AA, Papadopoulos EB, Shaffer B, Perales MA, Obeid KM, Young JH, Papanicolaou GA.
Han G, et al.
Transplant Cell Ther. 2024 Dec 17:S2666-6367(24)00811-X. doi: 10.1016/j.jtct.2024.12.010. Online ahead of print.
Transplant Cell Ther. 2024.
PMID: 39701288